NICE recommends BeiGene’s Brukinsa for MZL
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued a final draft guidance (FDG) recommending Brukinsa (zanubrutinib), from Sino-American biotech BeiGene (HKEX: 06160), for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.
“Brukinsa is a highly selective BTK inhibitor that has been shown in clinical studies and real-world use to provide high response rates with durable disease control for eligible patients with MZL,” said Dr Renata Walewska, Department of Hematology, University Hospitals Dorset, Bournemouth, UK. “This decision is a significant step forward for patients in England and Wales, providing them access to a new and targeted treatment option for relapsed/refractory MZL,” she added.
Brukinsa, which the NICE last year cleared for chronic lymphocytic leukemia (CLL), is the first-ever treatment to be recommended by the agency for MZL, BeiGene pointed out.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze